Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise
Researchers at St. Jude Children's Research Hospital have discovered that inhibiting the menin protein shows promise in treating myeloproliferative neoplasms. Preclinical studies in mice demonstrated improved survival rates and normalized blood cell counts.
Why it matters
This discovery offers a potential new therapeutic pathway for rare blood cancers, building on existing FDA-approved treatments for leukemia.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Graphical abstract. Credit: Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.06.008 Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds promise for treating myeloproliferative neoplasms. A new study from scientists at St. Jude Children's Research Hospital showed that inhibiting menin significantly extended survival and reversed multiple disease features in preclinical models. The findings were published today in Cancer Cell .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in